Skip to content
Screener

Reported November 12, 2026 · After market close

EPS-$0.28Beat by $0.06
EPS estimate-$0.34
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Paul Peter Tak

Next report

Date not yet announced

FAQ

When did Candel Therapeutics, Inc. report Q3 2026 earnings?
Candel Therapeutics, Inc. (CADL) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Candel Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.28 for Q3 2026.
Did Candel Therapeutics, Inc. beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.34 by $0.06.
How did Candel Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 33.3% from $-0.21.
Where can I find Candel Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-458316) and the 10-Q periodic report (0001193125-26-458380) directly on SEC EDGAR. The filing index links above go to sec.gov.